Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAGH | Q16775 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964103 | 0.89 | HAGH (0.66) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21951992 | 0.84 | HAGH (1.00) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21964046 | 0.83 | HAGH (0.84) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL24176460 | 0.83 | HAGH (0.67) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21963934 | 0.81 | HAGH (0.65) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21963935 | 0.79 | HAGH (0.81) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21964146 | 0.77 | HAGH (0.69) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL24176458 | 0.76 | HAGH (0.78) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21964125 | 0.76 | HAGH (0.67) | HAGHTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL21964058 | 0.76 | HAGH (0.67) | HAGHTDP1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874357-A | Metallobeta-lactamase inhibitors | 国家科学研究中心 | 2021-12-31 | — | — | CN | claimed |
| US-20220000841-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIVERSITÉ DE MONTPELLIER (FR) | 2022-01-06 | — | — | US | disclosed |
| CN-113874357-A | Metallobeta-lactamase inhibitors | 国家科学研究中心 | 2021-12-31 | — | — | CN | disclosed |
| EP-3880665-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Centre national de la recherche scientifique (FR) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099645-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000841-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, LCT, MGAM2 | HAGH 1320/4885TDP1 2693/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.